News
NERV
2.120
-2.75%
-0.060
Minerva Neurosciences, Inc. Revises November 12, 2026 KOL Event Transcript to Clarify Regulatory Statements
NASDAQ · 3d ago
Minerva Neurosciences Revises Transcript of Roluperidone FDA Event
TipRanks · 3d ago
Weekly Report: what happened at NERV last week (1109-1113)?
Weekly Report · 4d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Minerva Neurosciences (NERV) and Moderna (MRNA)
TipRanks · 11/09 13:01
Weekly Report: what happened at NERV last week (1102-1106)?
Weekly Report · 11/09 09:54
Minerva Neurosciences GAAP EPS of -$0.19 misses by $0.01
Seeking Alpha · 11/06 15:16
Minerva Neurosciences Q3 EPS $(0.19) Beats $(0.21) Estimate
Benzinga · 11/06 14:03
*Minerva Neurosciences 3Q Loss/Shr 19c >NERV
Dow Jones · 11/06 14:00
Minerva Neurosciences: Q3 Earnings Snapshot
Barchart · 11/06 08:07
Weekly Report: what happened at NERV last week (1026-1030)?
Weekly Report · 11/02 09:54
Russell 2000 estimated to drop 83 stocks in December rebalance - Stephens
Seeking Alpha · 10/29 19:44
Weekly Report: what happened at NERV last week (1019-1023)?
Weekly Report · 10/26 09:53
Weekly Report: what happened at NERV last week (1012-1016)?
Weekly Report · 10/19 09:53
Weekly Report: what happened at NERV last week (1005-1009)?
Weekly Report · 10/12 09:57
Weekly Report: what happened at NERV last week (0928-1002)?
Weekly Report · 10/05 09:57
Weekly Report: what happened at NERV last week (0921-0925)?
Weekly Report · 09/28 09:53
Weekly Report: what happened at NERV last week (0914-0918)?
Weekly Report · 09/21 09:53
Weekly Report: what happened at NERV last week (0907-0911)?
Weekly Report · 09/14 09:57
Weekly Report: what happened at NERV last week (0831-0904)?
Weekly Report · 09/07 09:52
Weekly Report: what happened at NERV last week (0824-0828)?
Weekly Report · 08/31 09:57
More
Webull provides a variety of real-time NERV stock news. You can receive the latest news about Minerva Neurosci through multiple platforms. This information may help you make smarter investment decisions.
About NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.